34171-43-2

Usage

Uses

Used in Cardiovascular Applications:
CHEMBRDG-BB 4016714 is used as an antihypertensive agent for treating high blood pressure. It helps to lower blood pressure by blocking the action of epinephrine on the heart and blood vessels, leading to a reduction in heart rate and blood vessel constriction.
Used in Chest Pain Management:
CHEMBRDG-BB 4016714 is used as an anti-anginal agent for managing chest pain. It helps to prevent the occurrence of angina by reducing the workload on the heart and improving blood flow to the heart muscle.
Used in Tremor Treatment:
CHEMBRDG-BB 4016714 is used as an anti-tremor medication for treating tremors. It works by blocking the action of epinephrine on the muscles, leading to a reduction in muscle tremors.
Used in Migraine Prevention:
CHEMBRDG-BB 4016714 is used as a prophylactic agent for preventing migraine headaches. It has been shown to be effective in reducing the severity and frequency of migraines by blocking the action of epinephrine on blood vessels in the brain.
Used in Various Pharmaceutical Forms:
CHEMBRDG-BB 4016714 is available in various forms, including tablets, extended-release capsules, and oral solutions. It is typically taken by mouth with or without food, making it a convenient and accessible treatment option for various conditions.

InChI:InChI=1/C7H10ClN3/c1-5-4-9-7(8)10-6(5)11(2)3/h4H,1-3H3

Upstream product

• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 124-40-3 dimethyl amine 

Downstream Products

• 771543-90-9 cis-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester 
• 771544-91-3 cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid ethyl ester 
• 771544-04-8 cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-nitro-benzylamide 

Relevant academic research and scientific papers

Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: In vitro profiling and in vivo evaluation

A series of pyrimidine analogues derived from ATC0175 were potent antagonists of human MCH-R1 in vitro. Significantly improved receptor selectivity was achieved with several analogues from this series, but no improvement in brain partitioning was noted. One example from this series was shown to inhibit food intake and decrease body weight in a chronic study. However no clear correlation between the pharmacodynamic effect and the pharmacokinetic data with respect to brain concentration was discernible leading us to conclude that the observed effect was most likely not due to interaction with the MCH-R1.

PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF

The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson’s disease, epilepsy, and addiction.

QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST

The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.